{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:36:46Z","timestamp":1788907006589,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Fluoroquinolones (FQs) are being used as second-line agents in the treatment of tuberculosis caused by multidrug-resistant strains. Ofloxacin (OFX) is being tried as a part of modified multidrug therapy regimens for leprosy. A preliminary study was carried out to evaluate the accumulation of FQs \u2013 OFX, levofloxacin (LFX), norfloxacin (NFX), and ciprofloxacin (CIF) in\n                      <jats:italic toggle=\"yes\">Mycobacterium smegmatis<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">M. smegmatis<\/jats:italic>\n                      were grown in Sauton's medium till log phase, harvested and resuspended in phosphate buffer (0.1 M, pH 7.2, Optical Density (OD) of 0.4\u20130.5) The suspensions were incubated with OFX, LFX, NFX, and CIF (10 \u03bcg\/ml) at 37\u00b0C. The drugs were estimated in the supernatants using spectrofluorimeteric methods. The experiments were also conducted with the addition of carbonyl cyanide m-chlorophenyl hydrazone (CCCP), a proton motive force inhibitor, at 100 \u03bcM, 10 min before and\/or immediately after the addition of the drugs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The time taken to achieve a Steady State Concentration (SSC) of OFX in\n                      <jats:italic toggle=\"yes\">M. smegmatis<\/jats:italic>\n                      was 3 min and the level of accumulation was 102 ng\/mg dry weight of the bacilli; with LFX the time for SSC was 5 min and the level of accumulation was 90 ng\/mg; in case of NFX the accumulation to SSC was 87 ng\/mg in 3 min. CIF accumulation attained a steady state (SSC level of 79 ng\/mg) in 4 min. The accumulation kinetics for NFX in\n                      <jats:italic toggle=\"yes\">M. smegmatis<\/jats:italic>\n                      using the spectrofluorimetric method is comparable with radioactive assays. Dose-related accumulation was observed with 10 \u03bcg\/ml exposure concentrations. The addition of CCCP failed to influence the accumulation of each of these quinolones.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The findings of dose-related accumulation of OFX, LFX NFX, and CIF suggest simple diffusion as the possible mechanism of transport of these drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_194_19","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T09:01:19Z","timestamp":1707728479000},"page":"34-38","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the Intracellular Accumulation of Fluoroquinolones in Mycobacteria by Fluorometric Assays"],"prefix":"10.4103","volume":"9","author":[{"given":"Nirmala","family":"Deo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divakar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnamurthy","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20240212","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.bi.64.070195.000333","article-title":"The envelope of mycobacteria","volume":"64","author":"Brennan","year":"1995","journal-title":"Annu Rev Biochem"},{"key":"R2-7-20240212","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/jb.172.3.1418-1423.1990","article-title":"Permeability barrier to hydrophilic solutes in Mycobacterium chelonei","volume":"172","author":"Jarlier","year":"1990","journal-title":"J Bacteriol"},{"key":"R3-7-20240212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1574-6968.1994.tb07194.x","article-title":"Mycobacterial cell wall: Structure and role in natural resistance to antibiotics","volume":"123","author":"Jarlier","year":"1994","journal-title":"FEMS Microbiol Lett"},{"key":"R4-7-20240212","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/AAC.00414-06","article-title":"Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: Evaluation ofin vitro and pharmacodynamic indices that best predictin vivo efficacy","volume":"51","author":"Shandil","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-7-20240212","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1517\/13543784.11.2.233","article-title":"Fluoroquinolones and tuberculosis","volume":"11","author":"Bryskier","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"R6-7-20240212","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance","volume":"3","author":"Ginsburg","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"R7-7-20240212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.33.1.1","article-title":"Mycobacteria and the new quinolones","volume":"33","author":"Leysen","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-7-20240212","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/32.6.797","article-title":"In vitro activities of quinolones against mycobacteria","volume":"32","author":"Garcia-Rodriguez","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"R9-7-20240212","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01966994","article-title":"Mode of action of the new quinolones: New data","volume":"10","author":"Hooper","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R10-7-20240212","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1128\/AAC.38.11.2623","article-title":"Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition","volume":"38","author":"Hoshino","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-7-20240212","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/AAC.40.2.491","article-title":"Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli","volume":"40","author":"Vila","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-7-20240212","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/jac\/48.6.787","article-title":"Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv","volume":"48","author":"Piddock","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"R14-7-20240212","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0923-2508(91)90114-P","article-title":"Chemical principles in the organization of lipid components in the mycobacterial cell envelope","volume":"142","author":"Minnikin","year":"1991","journal-title":"Res Microbiol"},{"key":"R15-7-20240212","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1128\/AAC.38.9.1991","article-title":"Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones","volume":"38","author":"Revel","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-7-20240212","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1128\/AAC.39.11.2466","article-title":"Intracellular accumulation of norfloxacin in Mycobacterium smegmatis","volume":"39","author":"Corti","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-7-20240212","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/AAC.42.4.795","article-title":"Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis","volume":"42","author":"Williams","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-7-20240212","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2460\/ajvr.1990.51.07.1065","article-title":"Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug","volume":"51","author":"Brown","year":"1990","journal-title":"Am J Vet Res"},{"key":"R20-7-20240212","first-page":"21","article-title":"Pharmacokinetic study comparing enrofloxacin and danofloxacin in calves","volume":"20","author":"Mckellar","year":"1997","journal-title":"J Vet Pharmacol Ther"},{"key":"R21-7-20240212","first-page":"413","article-title":"Fluoroquinolones: An old drug with new dimensions","volume":"7","author":"Shrivastav","year":"2018","journal-title":"Pharma Innovat J"},{"key":"R22-7-20240212","first-page":"577","article-title":"Clinical pharmacologic features of fluoroquinolone antimicrobial drugs","volume":"193","author":"Neer","year":"1988","journal-title":"J Am Vet Med Assoc"},{"key":"R24-7-20240212","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/AAC.41.2.274","article-title":"Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells","volume":"41","author":"Pascual","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-7-20240212","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1023\/A:1018871029244","article-title":"Distribution characteristics of levofloxacin and grepafloxacin in rat kidney","volume":"16","author":"Ito","year":"1999","journal-title":"Pharm Res"},{"key":"R26-7-20240212","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/AAC.32.4.438","article-title":"Routes of quinolone permeation in Escherichia coli","volume":"32","author":"Chapman","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-7-20240212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/AAC.38.2.163","article-title":"New quinolones and gram-positive bacteria","volume":"38","author":"Piddock","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-7-20240212","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.28.4.581","article-title":"The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro","volume":"28","author":"Wolfson","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-7-20240212","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/AAC.4.4.479","article-title":"Studies on the mechanism of action of nalidixic acid","volume":"4","author":"Bourguignon","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-7-20240212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1073\/pnas.82.2.307","article-title":"Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA","volume":"82","author":"Shen","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R32-7-20240212","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"R34-7-20240212","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.46.6.1875-1879.2002","article-title":"Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis","volume":"46","author":"Yoshimatsu","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-7-20240212","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/27.4.399","article-title":"Mechanism of quinolone uptake into bacterial cells","volume":"27","author":"Piddock","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"R38-7-20240212","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1128\/AAC.36.11.2506","article-title":"Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus","volume":"36","author":"Furet","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-7-20240212","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/31.6.865","article-title":"Accumulation and killing kinetics of fifteen quinolones for Escherichia coli Staphylococcus aureus and Pseudomonas aeruginosa","volume":"31","author":"Asuquo","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"R40-7-20240212","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.1279810","article-title":"Porins in the cell wall of mycobacteria","volume":"258","author":"Trias","year":"1992","journal-title":"Science"},{"key":"R41-7-20240212","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1016\/S0021-9258(18)53244-0","article-title":"Characterization of the channel formed by the mycobacterial porin in lipid bilayer membranes. Demonstration of voltage gating and of negative point charges at the channel mouth","volume":"268","author":"Trias","year":"1993","journal-title":"J Biol Chem"},{"key":"R42-7-20240212","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1128\/AAC.33.5.653","article-title":"Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes","volume":"33","author":"Pascual","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-7-20240212","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1128\/jb.178.13.3791-3795.1996","article-title":"Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump","volume":"178","author":"Liu","year":"1996","journal-title":"J Bacteriol"},{"key":"R44-7-20240212","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.40.8.1768","article-title":"Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra","volume":"40","author":"Kocag\u00f6z","year":"1996","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_194_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:20:16Z","timestamp":1787768416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_194_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_194_19","relation":{},"ISSN":["2212-5531"],"issn-type":[{"value":"2212-5531","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}